Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00654758 | A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 33 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01225302 |
| A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) |
| completed |
| Phase 1 |
| 12 |
| AbbVieINDUSTRY |
| 0 |
| Nov 21, 2017 |
| clinicaltrials |
| NCT00528281 | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 4 | Nov 17, 2017 | clinicaltrials |
| NCT00619424 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors | completed | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00946673 | Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Stanford UniversityOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT01995188 | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT03001609 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT01051934 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 49 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | completed | Phase 1 | 87 | Genentech, Inc.INDUSTRY | 2 | Jun 7, 2017 | clinicaltrials |
| NCT00731952 | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | completed | Phase 1 | 21 | University of VirginiaOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT01069757 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 16 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01251796 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 9 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT01005797 | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | completed | Phase 1 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00444015 | Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01647711 | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | completed | Phase 1 | 35 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
| NCT00073723 | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 75 | Celgene CorporationINDUSTRY | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00876460 | BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00776698 | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00975182 | A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01839955 | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 | 12 | Neelesh Sharma MD PhDOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01605916 | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | completed | Phase 1 | 6 | MorphotekINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Nasser Hanna, M.D.OTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT00850785 | Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer(DRibble) | completed | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT01723800 | PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00496275 | Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC | completed | Phase 1 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 26, 2016 | clinicaltrials |
| NCT00994123 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 162 | Merrimack PharmaceuticalsINDUSTRY | 6 | Aug 22, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00826449 | Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01134016 | Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects(Hocena) | completed | Phase 1 | 13 | Golden Biotechnology CorporationINDUSTRY | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT02040064 | Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients(GEFTREM) | completed | Phase 1 | 27 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT00933777 | SORAVE - Sorafenib and Everolimus in Solid Tumors(SORAVE) | completed | Phase 1 | 36 | University of CologneOTHER | 1 | May 25, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 22, 2017source: clinicaltrials